Literature DB >> 17301215

Serum antibody responses in Ethiopian meningitis patients infected with Neisseria meningitidis serogroup A sequence type 7.

Gunnstein Norheim1, Abraham Aseffa, Mohammed Ahmed Yassin, Getahun Mengistu, Afework Kassu, Dereje Fikremariam, Wegene Tamire, Yared Merid, E Arne Høiby, Dominique A Caugant, Elisabeth Fritzsønn, Torill Tangen, Tsegaye Alebel, Degu Berhanu, Morten Harboe, Einar Rosenqvist.   

Abstract

To elucidate critical components of protective immune responses induced during the natural course of serogroup A meningococcal disease, we studied acute-, early-convalescent-, and late-convalescent-phase sera from Ethiopian patients during outbreaks in 2002 to 2003. Sera were obtained from laboratory-confirmed patients positive for serogroup A sequence type 7 (ST-7) meningococci (A:4/21:P1.20,9) (n = 71) and from Ethiopian controls (n = 113). The sera were analyzed using an enzyme-linked immunosorbent assay to measure levels of immunoglobulin G (IgG) against serogroup A polysaccharide (APS) and outer membrane vesicles (OMVs) and for serum bactericidal activity (SBA) using both rabbit and human complement sources. Despite relatively high SBA titers and high levels of IgG against APS and OMVs in acute-phase patient sera, significant increases were seen in the early convalescent phase. Antibody concentrations returned to acute-phase levels in the late convalescent phase. Considering all patients' sera, a significant but low correlation (r = 0.46) was observed between SBA with rabbit complement (rSBA) using an ST-5 reference strain and SBA with human complement (hSBA) using an ST-7 strain from Ethiopia. While rSBA demonstrated a significant linear relation with IgG against APS, hSBA demonstrated significant linear relationships with IgG against both APS and OMV. This study indicates that antibodies against both outer membrane proteins and APS may be important in providing the protection induced during disease, as measured by hSBA. Therefore, outer membrane proteins could also have a role as components of future meningococcal vaccines for the African meningitis belt.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17301215      PMCID: PMC1865611          DOI: 10.1128/CVI.00008-07

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  60 in total

1.  [CEREBROSPINAL MENINGITIS IN AFRICA].

Authors:  L LAPEYSSONNIE
Journal:  Bull World Health Organ       Date:  1963       Impact factor: 9.408

2.  A fractionating column for analysis of nucleic acids.

Authors:  J D MANDELL; A D HERSHEY
Journal:  Anal Biochem       Date:  1960-06       Impact factor: 3.365

3.  Naturally-acquired immunity to Neisseria meningitidis group A.

Authors:  Jacob Amir; Lesile Louie; Dan M Granoff
Journal:  Vaccine       Date:  2005-01-11       Impact factor: 3.641

4.  Antibody response in group B meningococcal disease determined by enzyme-linked immunosorbent assay with serotype 15 outer membrane antigen.

Authors:  S Harthug; E Rosenqvist; E A Høiby; T W Gedde-Dahl; L O Frøholm
Journal:  J Clin Microbiol       Date:  1986-12       Impact factor: 5.948

5.  Immune responses against major outer membrane antigens of Neisseria meningitidis in vaccinees and controls who contracted meningococcal disease during the Norwegian serogroup B protection trial.

Authors:  E Wedege; E A Høiby; E Rosenqvist; G Bjune
Journal:  Infect Immun       Date:  1998-07       Impact factor: 3.441

6.  Standardization and a multilaboratory comparison of Neisseria meningitidis serogroup A and C serum bactericidal assays. The Multilaboratory Study Group.

Authors:  S E Maslanka; L L Gheesling; D E Libutti; K B Donaldson; H S Harakeh; J K Dykes; F F Arhin; S J Devi; C E Frasch; J C Huang; P Kriz-Kuzemenska; R D Lemmon; M Lorange; C C Peeters; S Quataert; J Y Tai; G M Carlone
Journal:  Clin Diagn Lab Immunol       Date:  1997-03

Review 7.  Polysaccharide vaccines for preventing serogroup A meningococcal meningitis.

Authors:  M Patel; C K Lee
Journal:  Cochrane Database Syst Rev       Date:  2005-01-25

8.  Factors influencing susceptibility to meningococcal disease during an epidemic in The Gambia, West Africa.

Authors:  B M Greenwood; A M Greenwood; A K Bradley; K Williams; M Hassan-King; F C Shenton; R A Wall; R J Hayes
Journal:  J Infect       Date:  1987-03       Impact factor: 6.072

9.  Human antibody responses to A and C capsular polysaccharides, IgA1 protease and transferrin-binding protein complex stimulated by infection with Neisseria meningitidis of subgroup IV-1 or ET-37 complex.

Authors:  N Brieske; M Schenker; T Schnibbe; M J Quentin-Millet; M Achtman
Journal:  Vaccine       Date:  1999-02-26       Impact factor: 3.641

10.  Humoral immune responses to Neisseria meningitidis in children.

Authors:  A J Pollard; R Galassini; E M van der Voort; R Booy; P Langford; S Nadel; C Ison; J S Kroll; J Poolman; M Levin
Journal:  Infect Immun       Date:  1999-05       Impact factor: 3.441

View more
  4 in total

1.  Specificity of subcapsular antibody responses in Ethiopian patients following disease caused by serogroup A meningococci.

Authors:  Gunnstein Norheim; Abraham Aseffa; Mohammed Ahmed Yassin; Getahun Mengistu; Afework Kassu; Dereje Fikremariam; Wegene Tamire; Yared Merid; E Arne Høiby; Dominique A Caugant; Elisabeth Fritzsønn; Torill Tangen; Berhanu Melak; Degu Berhanu; Morten Harboe; Jan Kolberg; Einar Rosenqvist
Journal:  Clin Vaccine Immunol       Date:  2008-03-12

2.  Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults.

Authors:  H Findlow; B D Plikaytis; A Aase; M C Bash; H Chadha; C Elie; G Laher; J Martinez; T Herstad; E Newton; S Viviani; C Papaspyridis; P Kulkarni; M Wilding; M P Preziosi; E Marchetti; M Hassan-King; F M La Force; G Carlone; R Borrow
Journal:  Clin Vaccine Immunol       Date:  2009-05-27

3.  Molecular studies of meningococcal and pneumococcal meningitis patients in Ethiopia.

Authors:  Wude Mihret; Berit Sletbakk Brusletto; Reidun Øvstebø; Anne-Marie Siebke Troseid; Gunnstein Norheim; Yared Merid; Afework Kassu; Workeabeba Abebe; Samuel Ayele; Mezgebu Silamsaw Asres; Lawrence Yamuah; Abraham Aseffa; Beyene Petros; Dominique A Caugant; Petter Brandtzaeg
Journal:  Innate Immun       Date:  2019-04       Impact factor: 2.680

4.  Population-Level Persistence of Immunity 2 Years After the PsA-TT Mass-Vaccination Campaign in Mali.

Authors:  Nicole E Basta; Ray Borrow; Abdoulaye Berthe; Awa Traoré Eps Dembélé; Uma Onwuchekwa; Kelly Townsend; Rahamatou M Boukary; Lesley Mabey; Helen Findlow; Xilian Bai; Samba O Sow
Journal:  Clin Infect Dis       Date:  2015-11-15       Impact factor: 9.079

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.